GSA 10

Hedgehog pathway activator; Activates Smoothened (SMO)

More Views

From: 231 USD

Options

* Required Fields

Catalog # (Select a product)
Hedgehog pathway activator; Activates Smoothened (SMO)
From: 231 USD

Overview

GSA 10 is an agonist of Smoothened (SMO), a cell surface receptor and mediator of the hedgehog signaling pathway. It is a quinolinecarboxamide derivative that binds in a distinct binding pocket from cyclopamine. GSA10 is active at an EC₅₀ of 1.2 μM in an alkaline phosphatase-based mouse mesenchymal cell line (C3H10T1/2) differentiation assay (Gorojankina et al.).

DIFFERENTIATION
· Promotes differentiation of multipotent mesenchymal progenitor cells into osteoblasts (Gorojankina et al.).
Alternative Names:
Not applicable
CAS Number:
300833-95-8
Chemical Formula:
C₂₆H₃₀N₂O₅
Molecular Weight:
450.5 g/mol
Purity:
≥ 95%
Pathway:
Hedgehog
Target:
SMO

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Molecular pharmacology 2013

Discovery, molecular and pharmacological characterization of GSA-10, a novel small-molecule positive modulator of Smoothened.

Gorojankina T et al.

Abstract

Activation of the Smoothened (Smo) receptor mediates Hedgehog (Hh) signaling. Hh inhibitors are in clinical trials for cancer, and small-molecule Smo agonists may have therapeutic interests in regenerative medicine. Here, we have generated and validated a pharmacophoric model for Smo agonists and used this model for the virtual screening of a library of commercially available compounds. Among the 20 top-scoring ligands, we have identified and characterized a novel quinolinecarboxamide derivative, propyl 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido) benzoate, (GSA-10), as a Smo agonist. GSA-10 fits to the agonist pharmacophoric model with two hydrogen bond acceptor groups and four hydrophobic regions. Using pharmacological, biochemical, and molecular approaches, we provide compelling evidence that GSA-10 acts at Smo to promote the differentiation of multipotent mesenchymal progenitor cells into osteoblasts. However, this molecule does not display the hallmarks of reference Smo agonists. Remarkably, GSA-10 does not recognize the classic bodipy-cyclopamine binding site. Its effect on cell differentiation is inhibited by Smo antagonists, such as MRT-83, SANT-1, LDE225, and M25 in the nanomolar range, by GDC-0449 in the micromolar range, but not by cyclopamine and CUR61414. Thus, GSA-10 allows the pharmacological characterization of a novel Smo active site, which is notably not targeted to the primary cilium and strongly potentiated by forskolin and cholera toxin. GSA-10 belongs to a new class of Smo agonists and will be helpful for dissecting Hh mechanism of action, with important implications in physiology and in therapy.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.